Viracta Therapeutics, Inc. (NASDAQ:VIRX – Get Rating) – Investment analysts at SVB Leerink upped their Q1 2023 earnings per share estimates for shares of Viracta Therapeutics in a research report issued to clients and investors on Tuesday, March 14th. SVB Leerink analyst A. Berens now expects that the company will post earnings of ($0.32) per share for the quarter, up from their prior forecast of ($0.47). The consensus estimate for Viracta Therapeutics’ current full-year earnings is ($1.20) per share. SVB Leerink also issued estimates for Viracta Therapeutics’ Q2 2023 earnings at ($0.27) EPS, Q3 2023 earnings at ($0.27) EPS, Q4 2023 earnings at ($0.27) EPS, FY2023 earnings at ($1.12) EPS, FY2024 earnings at ($1.36) EPS, FY2025 earnings at ($0.62) EPS and FY2026 earnings at ($0.68) EPS.
Several other analysts have also recently commented on VIRX. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of Viracta Therapeutics in a research report on Tuesday, March 14th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 target price on shares of Viracta Therapeutics in a research report on Tuesday, March 14th.
Viracta Therapeutics Stock Performance
Institutional Trading of Viracta Therapeutics
A number of institutional investors have recently bought and sold shares of the company. Ensign Peak Advisors Inc boosted its position in Viracta Therapeutics by 4.8% during the second quarter. Ensign Peak Advisors Inc now owns 63,406 shares of the company’s stock valued at $246,000 after purchasing an additional 2,891 shares during the last quarter. Geode Capital Management LLC boosted its position in Viracta Therapeutics by 3.0% during the fourth quarter. Geode Capital Management LLC now owns 224,438 shares of the company’s stock valued at $327,000 after purchasing an additional 6,502 shares during the last quarter. Cubist Systematic Strategies LLC boosted its position in Viracta Therapeutics by 65.5% during the third quarter. Cubist Systematic Strategies LLC now owns 22,371 shares of the company’s stock valued at $96,000 after purchasing an additional 8,854 shares during the last quarter. State Street Corp boosted its position in Viracta Therapeutics by 2.3% during the first quarter. State Street Corp now owns 588,603 shares of the company’s stock valued at $2,802,000 after purchasing an additional 13,514 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in Viracta Therapeutics during the fourth quarter valued at $29,000. Institutional investors and hedge funds own 32.35% of the company’s stock.
About Viracta Therapeutics
Viracta Therapeutics, Inc a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas.
- Get a free copy of the StockNews.com research report on Viracta Therapeutics (VIRX)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Viracta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viracta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.